TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib.
Saved in:
| Title: | TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. |
|---|---|
| Authors: | Roeper J; Department of Internal Medicine-Oncology, Carl v. Ossietzky University of Oldenburg, Pius-Hospital, Oldenburg, Germany.; Department of Hematology and Oncology, Pius-Hospital, Oldenburg, Germany.; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany., Christopoulos P; Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), University Hospital, Heidelberg, Germany., Falk M; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.; Hematopathology Hamburg, Hamburg, Germany., Heukamp LC; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.; Hematopathology Hamburg, Hamburg, Germany., Tiemann M; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.; Hematopathology Hamburg, Hamburg, Germany., Stenzinger A; Department of General Pathology and Pathological Anatomy, University Hospital, Heidelberg, Germany., Thomas M; Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), University Hospital, Heidelberg, Germany., Griesinger F; Department of Internal Medicine-Oncology, Carl v. Ossietzky University of Oldenburg, Pius-Hospital, Oldenburg, Germany.; Department of Hematology and Oncology, Pius-Hospital, Oldenburg, Germany.; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany. |
| Source: | Translational lung cancer research [Transl Lung Cancer Res] 2022 Jan; Vol. 11 (1), pp. 4-13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Pioneer Bioscience Publishing Company Country of Publication: China NLM ID: 101646875 Publication Model: Print Cited Medium: Print ISSN: 2218-6751 (Print) Linking ISSN: 22186751 NLM ISO Abbreviation: Transl Lung Cancer Res Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
